Research Article

A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma

Table 1

Characteristics of the PANKRAS II study subjects according to the groups considered in the comparative analysis.

DiagnosisNumber of samplesGender (M/F)Age (mean ± sd.)

Pancreatic cancer (PDAC)15692/6466 ± 13
 Head (ICD9: 157.0)9745/5267 ± 13
 Body (ICD9: 157.1)1612/468 ± 10
 Tail (ICD9: 157.2)108/260 ± 11
 Other (ICD9: 157.8)168/865 ± 13
 Unspecified (ICD9: 157.9)1712/566 ± 15
Other pancreatic diseases (OPD)152117/3552 ± 14
 Acute pancreatitis (ICD9: 577.0)3322/1159 ± 15
 Chronic pancreatitis (ICD9: 577.1)11095/1550 ± 13
 Islet neoplasm (ICD9: 211.7)30/364 ± 3
 Benign pancreatic neoplasms (ICD9: 211.6)60/651 ± 18
Nonpancreatic conditions (NPC)3020/1062 ± 14

Total338

() ICD9 codes: 454 (2), 540, 735 (2), 807, 808, 812, 813, 820, 550.9 (4), 553.21 (2), 553.3, 560.9, 603.9, 735.0, 806.4, 812.09, 815.02, 820.2, 820.8, 821.2, 823.0, 823.90, 824.0, 839.0.